Revenio Group Oyj - Total number of voting rights and capital

Revenio Group Corporation: INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Revenio Group Corporation Stock Exchange Release   15 May 2013, 10:30 hrs

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

70,000 new share subscriptions based on the company's 2007A stock options by the
number of 55,000, 2007B stock options by the number of 7,500 and 2007C stock
options by the number of 7,500 approved by the Board of Directors of Revenio
Group Corporation on 3 May 2013, have been entered into the trade register
today. The share subscription price under 2007A option rights is EUR 5.99 per
share, under 2007B option rights 2.47 per share and under 2007C option rights
EUR 2.41 per share. The subscription period for 2007A options is from 1 May
2009 to 1 May 2013, for 2007B options from 1 November 2010 to 1 November 2014
and for 2007C options from 1 May 2012 to 1 May 2016.

After these subscriptions, the number of Revenio Group Corporation's shares and
votes will rise to 7,838,909. These increases were recorded in their entirety in
the unrestricted shareholders' equity fund.

According to the Trade Register, a delay in transferring the new shares to the
shareholders accounts occurs due to technical problems.

Revenio Group Corporation has applied for the listing of its new shares on the
NASDAQ OMX Helsinki in the same series as the company's existing shares.
According to the current estimate, the new shares will be listed on 15 May 2013.

Revenio Group Corporation

Olli-Pekka Salovaara

President and CEO

For further information, please contact:

Olli-Pekka Salovaara, President & CEO, +358 (0)40 567 5520 (mobile)

olli-pekka.salovaara@revenio.fi

http://www.revenio.fi/

DISTRIBUTION:

NASDAQ OMX Helsinki

Financial Supervisory Authority (FIN-FSA)

Key media

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The
Revenio Health Tech segment comprises the operations of Icare Finland Oy. The
widely patented Icare product family is the current cornerstone of the Group's
success. Revenio seeks vigorous growth in health technology, both organically
and through acquisitions and mergers.

The Revenio Group also includes other business operations, which are grouped
under the Technology and Services segment. This segment's operations have a
shared global market and represent the cutting edge of technology products and
services in their industry. These businesses are extremely profitable in their
industries and generate positive cash flow.

In 2012, the Revenio Group's net sales totaled EUR 25.4 million, with its
operating margin standing at 19.4 percent. The Revenio Group Corporation is
listed on NASDAQ OMX Helsinki.




[HUG#1701473]